Sign in
Taking people in United StatesNo phase

Checks bone density in people receiving immunotherapy for several cancers

Measures bone density and structure in adults with cancer receiving anti-PD-1 immunotherapy.

Key facts

Who runs it
Jessica Mezzanotte Sharpe
Where
Nashville, United StatesSee the site
Trial code
Registry title
Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy
Status
Recruiting
People taking part
25 people, planned
Started
25 Aug 2025
Expected to end
1 Jul 2028
Type of study
Interventional
Treatments tested
  • Dual-Energy X-ray Absorptiometry (DXA)
  • High Resolution peripheral Quantitative Computed Tomography (HRpQCT)
Record updated
6 May 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with cancer who are about to start, or just started, anti-PD-1 immunotherapy with treatment meant to remove all of the disease. It studies how this therapy affects bones.

Age
18 years or older.
Sex
All sexes can join.
Disease stage
Cancer treated with the aim of removing all of the disease. People with metastatic disease cannot join.
Earlier treatment
Planning to start anti-PD-1 immunotherapy (alone or with chemotherapy), or within the first four weeks of it. No denosumab, zoledronic acid or other bisphosphonate in the last six months.

Main reasons for not taking part

  • Metastatic disease
  • Planned treatment with two immune checkpoint inhibitors together
  • Known osteoporosis or osteopenia
  • Fractures in the pelvis, hips/femurs, thoracic spine or lumbar spine
  • Pregnant or breastfeeding

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Age ≥ 18 years
  • Patients planning to start or within the first four weeks of treatment with anti-PD-1 immune checkpoint inhibitor therapy either alone or in combination with chemotherapy for curative intent for a known cancer diagnosis (use of immunotherapy must be FDA-approved and not experimental)
  • Life expectancy of at least 12 months per the discretion of the treating physician

Who cannot take part

  • Patients ineligible for anti-PD-1 therapy
  • Patients planning treatment with dual immune checkpoint inhibitor therapy
  • Planned or previous treatment with denosumab, zoledronic acid, or other bisphosphonate therapy in the last six months
  • Patients with metastatic disease
  • Parathyroid gland disorders, rheumatoid arthritis (unless well-controlled off active biologic therapy without chronic steroid use), CKD stage IV/V, or ESRD
  • Medical or psychiatric co-morbidities that, in the opinion of the treating physician, would prevent the patient from successfully participating in the study
  • Bony fractures in the pelvis, bilateral hips/femurs, thoracic spine, or lumbar spine
  • Known osteoporosis or osteopenia
  • Inability to comply with study procedures
  • Inability to lie flat for 20-25 minutes during an imaging session
  • Pregnant or breastfeeding patients

Where in United States

  • Vanderbilt-Ingram Cancer CenterNashville, United StatesContact: Jennifer Whisenant, PhDTaking people

About the trial

What the trial wants to find out

Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment and work by blocking protein interactions that normally prevent the immune system from recognizing and destroying cancer cells. However, these agents, now approved for over 15 types of cancers and for both early-stage and metastatic disease, are capable of causing inflammation in any organ system of the body that can lead to organ damage, dysfunction, and even death in rare cases. Some patients may suffer acute and treatable complications like joint pain, but some may have irreversible complications like hypothyroidism that requires daily, life-long medication. It is therefore important to fully understand the different types of damage ICIs can cause to better monitor patients receiving ICI therapy.

Read full original descriptionShow less

A rising concern from recent reports in the literature is that ICIs may weaken bone and increase the risk of fractures. In this study, the investigators aim to characterize how ICIs impact the bone by examining several factors in patients undergoing curative-intent ICI treatment either alone or in combination with chemotherapy: bone mineral density, bone volume, and markers of bone turnover in the blood. The study will use two imaging techniques to assess bone mineral density and volume. DXA (dual X-ray absorptiometry) imaging uses low-dose X-rays to measure how dense (or strong) bones are and is often used to diagnose or assess the risk of osteoporosis. High-resolution peripheral quantitative computed tomography (HRpQCT) is a 3D imaging technology that can quantify bone structure and volume and offers high resolution that can be used to assess bone in smaller bones of the peripheral skeleton.

The investigators hypothesize that ICI treatment will weaken bones and increase the risk of fractures. As ICI therapy is relatively new, a rising number of patients may be at risk of fractures or have low bone density that is not being monitored because there are no guidelines in place notifying physicians of this potential risk to patients. This is study will provide important preliminary data that will be the basis for larger studies in the future aiming to better monitor and potentially treat bone weakening in patients treated with ICIs to reduce the pain, inconvenience, and complications from fragility fractures.

The group in the trial

  • Bone mineral density scans (DXA and HRpQCT)Treatment being tested

    Patients undergo two research bone mineral density scans (DXA and HRpQCT) at three time points: baseline, 4-6 months during immunotherapy, and after 12 months of immunotherapy

    Treatment: Dual-Energy X-ray Absorptiometry (DXA) and High Resolution peripheral Quantitative Computed Tomography (HRpQCT)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Pilot Study Assessment of Bone Mineral Density Changes During Treatment With Anti-PD-1 Immunotherapy Agents
Plain-language title
Checks bone density in people receiving immunotherapy for several cancersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
6 May 2026